BEIJING, Feb. 8 /PRNewswire-FirstCall/ -- Hiru Corporation (PINKSHEETS: HIRU) (www.hirucorporation.com) and its subsidiary Jiangxi RongYu Pharmaceutical Group, Inc. (www.jxrongyuyy.com) announce that one of the company's products has been officially added onto the National Essential Drugs List. [more]
PORTLAND, Ore., Feb. 8 /PRNewswire/ -- Rapid developments in the pharmaceutical industry have led to a steady increase in the use and cost of "specialty" medications to treat chronic conditions such as arthritis and psoriasis. This has led to some inappropriate selection of these medications, higher overall drug costs and medication coverage being spread over both pharmacy and medical benefits. Regence has introduced a new solution with Medication Cost Integration (MCI), which covers all medications under a single medication benefit. MCI is now available as part of the company's new self-insured suite of services, Integrated Health Solutions. [more]
DEERFIELD, Ill.--(BUSINESS WIRE)--Feb 8, 2010 - In support of Rare Disease Day 2010, set for February 28, Lundbeck Inc. today launched the Raise Your Hand to Fight Rare Diseases campaign. The web-based initiative is designed to generate support for people with rare diseases and is being conducted in partnership with the National Organization for Rare Disorders (NORD), the sponsor of Rare Disease Day in the United States. [more]
ROCKVILLE, Md., Feb. 8 /PRNewswire-USNewswire/ -- The first results from a large-scale study of key antimalarial medicines in ten Sub-Saharan African countries reveal that a high percentage of medicines circulating on national markets are of substandard quality and thus may contribute to the growth of drug-resistant strains of Plasmodium falciparum, the most virulent form of malaria. The findings, released today by the Promoting the Quality of Medicines (PQM) Program, a USAID-funded program implemented by the U.S. Pharmacopeial Convention (USP), are for three countries surveyed in the study -- Madagascar, Senegal and Uganda. [more]
Mississauga, ON – February 8, 2010 – When it comes to symptoms of menopause like hot flashes, weight gain or trouble sleeping, chances are most women wouldn’t hesitate to speak to their doctor. But there is another common – and equally distressing – effect of menopause that many women just keep to themselves. The Big Ow, also known as vaginal atrophy, will affect as many as two million Canadian women in the next 10 years1 – but most are too shy or embarrassed to talk about it, even with their doctor. [more]
JEFFERSON, NY, Feb. 8, 2010--The Minnesota Board of Pharmacy has revised the language of an important Frequently Asked Question (FAQ) to ensure that payments to Minnesota health care practitioners for participation in bona fide market and opinion research are NOT prohibited or restricted. [more]
KRAKOW, Poland, Feb. 8, 2010-In recent years the pharmaceutical distribution market in Poland has seen many changes. The wholesale distribution segment has experienced consolidation, including combinations between leading players, as well as the privatisation of State Treasury outlets. New forms of distribution have also been developed, such as direct/DTP distribution. [more]
WASHINGTON, Feb. 5 /PRNewswire-USNewswire/ -- The Family Research Council today criticized a decision by the Obama Administration to require military bases worldwide to carry Levonorgestrel, or 'Plan B.' [more]
WASHINGTON, Feb. 5 - A recent article in the Scandia Journal reported that biotechnology is helping to improve our knowledge of many devastating illnesses, and has armed patients and their doctors with exciting new diagnostics and treatments to battle disease. [more]
JERUSALEM--(BUSINESS WIRE)--Feb 5, 2010 - Teva Pharmaceutical Industries Ltd. announced today that several of its subsidiaries in the United States reached a settlement in principle to resolve claims brought by Ven-A-Care of the Florida Keys, Inc. on behalf of the United States, Texas, Florida, and California under federal and state False Claims Acts. [more]
Melbourne, Australia — 5 February 2010 - Biota Holdings Limited (ASX:BTA) today announced that it had received written notification from GlaxoSmithKline that Relenza sales were $462 million and indicative royalties were $32.6 million, for the three months ended 31 December 2009. The figures were calculated on an Australian dollar exchange rate of 1.8182 to the UK pound, although the actual payment will be calculated on exchange rates at 30 April 2010. Biota will report first half indicative Relenza royalty income of $56.7 million (2008: $3.8m) when it releases its Interim Report on 17 February 2010. [more]
MELBOURNE, Australia--(BUSINESS WIRE)--Feb 5, 2010 - Biota Holdings Limited today announced that it had received written notification from GlaxoSmithKline that Relenza sales were $462 million and indicative royalties were $32.6 million, for the three months ended 31 December 2009. [more]
PARIS and LAUSANNE, Switzerland, February 4/PRNewswire/ -- Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer. Other launches are planned shortly, notably in Germany and Portugal. [more]
DALLAS, Feb. 4 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill. [more]
SAN ANTONIO, Feb. 4 /PRNewswire-USNewswire/ -- Research presented at the American Academy of Pain Medicine's 26th Annual Meeting provides early published data analyzing information gathered from California's prescription monitoring program, known as the Controlled Substances Utilization Review and Evaluation System (CURES). [more]
WASHINGTON, February 04, 2010 /PRNewswire-USNewswire/ -- A new report, , released today by the Trust for America's Health (TFAH), the Infectious Diseases Society of America (IDSA), and the Robert Wood Johnson Foundation (RWJF), found that more than 30 percent of adults ages 65 and older had not been immunized against pneumonia in 36 states as of 2008. The U.S. Centers for Disease Control and Prevention (CDC) and other experts recommend that all seniors should be vaccinated against pneumonia, which is a one-time shot for most individuals, since seniors who get the seasonal flu are at risk for developing pneumonia as a complication. [more]
PITTSBURGH, Feb. 4 /PRNewswire-FirstCall/ -- Mylan Inc. (NASDAQ:MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine Besylate and Atorvastatin Calcium Tablets 2.5/10 mg, 2.5/20 mg, 2.5/40 mg, 5/10 mg, 5/20 mg, 5/40 mg, 5/80 mg, 10/10 mg, 10/20 mg, 10/40 and 10/80 mg. This product is the generic version of Caduet® Tablets, which combine the long-acting calcium channel blocker amlodipine besylate with the synthetic lipid-lowering agent atorvastatin calcium. [more]
WOODLAND HILLS, Calif., Feb. 4 /PRNewswire/ -- Imagine having to face the daily struggle of taking six or more different medications a day to manage a chronic health condition; add to this the worry of missing or taking a dose incorrectly. For Anthem Blue Cross (Anthem) Medi-Cal members, that daily struggle will now be simplified to help increase medication adherence and reduce medication errors. [more]
WOODLAND HILLS, Calif., Feb. 4 /PRNewswire/ -- Imagine having to face the daily struggle of taking six or more different medications a day to manage a chronic health condition; add to this the worry of missing or taking a dose incorrectly. For Anthem Blue Cross (Anthem) Medi-Cal members, that daily struggle will now be simplified to help increase medication adherence and reduce medication errors. [more]
SOMERSET, N.J., Feb. 4, 2010 (GLOBE NEWSWIRE) -- inVentiv Selling Solutions, a division of inVentiv Health (Nasdaq:VTIV), today launched a new sales model, known as "Selling2Scale," to drive the commercial success of its clients' pharmaceutical products through strategic outsourcing solutions. [more]
Mergers & Acquisitions, Partnerships, & Collaborations 2010 – Review and Outlook
This PharmaLive Special Report analyzes the healthcare industry’s M&As of 2009, providing a comprehensive listing of companies’ M&A activity and detailing the top 20 deals within each of the Pharmaceutical, Biotechnology, Specialty, and Medical Device sectors, and previews potential M&A activity within the healthcare arena for 2010.
The introductory rate of $395 expires February 17, 2010.
